Home » Markets » BioNTech and Pfizer's coronavirus vaccine shows potential in human trial
BioNTech and Pfizer's coronavirus vaccine shows potential in human trial
Promising anti-viral drug remdesivir cleared for use in coronavirus fight
Insight from Fox News medical contributor Dr. Marc Siegel.
FRANKFURT (Reuters) – A COVID-19 vaccine developed by German biotech firm BioNTech and U.S. pharmaceutical giant Pfizer has shown potential and was found to be well tolerated in early-stage human trials, the companies said on Wednesday.
Continue Reading Below
The drug is one of 17 being tested on humans in a frantic global race to find a vaccine the world is counting on to end a pandemic that has infected 10.5 million people and killed more than half a million so far.
The potential treatment is the fourth early-stage COVID-19 drug to show promise in human testing, along with projects involving Moderna, CanSino Biologics and Inovio Pharmaceuticals.
TOKYO DISNEY REOPENS, SENDING MICKEY MOUSE FANS 'OVER THE MOON'
BioNTech said testing of two dosages of its BNT162b1 drug on 24 healthy volunteers showed that after 28 days they had developed higher levels of COVID-19 antibodies than typically seen in infected people.
The higher of the two doses – both administered via two injections within three weeks of one another – was followed by a short fever in three out of four participants after the second shot.
A third dosage, tested at a higher concentration in a separate group, was not repeated after the first shot because of injection pain.
PICKING A HEALTH CARE PLAN: HOW TO DECIDE BETWEEN A PPO AND HMO
"These first trial results show that the vaccine yields immune activity and causes a strong immune response," said BioNTech's co-founder and Chief Executive Officer Ugur Sahin.